Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Endocrine 1

Conditions

Neuroendocrine Tumors 4Sarcoma 2Neoplasms 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Lymphoma 1Cholangiocarcinoma 1Carcinoid Tumor 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1

Interventions

Temozolomide 6Cyclophosphamide 4antineoplaston AS 2-1 3antineoplaston A10 3Radiotherapy 3Filgrastim 3sargramostim 2aldesleukin 2Vincristine 2Thalidomide 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Irinotecan 2Donepezil 2Cisplatin 2Carmustine 2Bevacizumab 2veliparib 1trametinib 1temsirolimus 1surufatinib 1spartalizumab 1sonidegib 1ribociclib 1reolysin 1plerixafor 1ganitumab 1fosbretabulin 1entinostat 1dactolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroectodermal Tumors, Primitive × surufatinib × Clear all
NCT02549937 2024-07-10

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Hutchmed

Phase 1/2 Completed
130 enrolled 30 charts
EndocrineSarcoma

Carcinoid Tumor, Neoplasms, Sarcoma, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡